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Statements
as part of the thesis
Pre-clinical development of anginex
and design of small-peptide mimetics
by Ruud P.M. Dings
Maastricht, 3 July 2003
1. Anti-parallel ß-sheet structure and preponderance of positively
charged and hydrophobic residues, is the recurring structural/
compositional theme for most anti-angiogenic compounds,
(this thesis)
2. Partial peptide-mimetic 6DBF7 is the first EC-specific molecule
designed as a substitute for an angiostatic inhibitory peptide.
(this thesis)
3. Genentech's Avastin, like anginex, proves that angiogenesis
inhibition can be a very powerful therapeutic treatment against
cancer in combination with conventional chemotherapy,
(this thesis)
4. There is no such thing as a panacea.
5. Having hope can be naive, but sometimes that's all one has.
6. Deadlines increase productivity, but unfortunately not often quality.
7. The nearly one to one exchange value between the American
Dollar and the Euro in 2002 made it very clear that the stipend
of the average Dutch Ph.D. student is much higher than that of
the average American Ph.D. student.
8. Blessed be the people with a conscience, for they are the cursed
of the world.
9. A result of being perfectly satisfied is that you always desire more.
